TheraRadar
← Back
Data updated: May 24, 2026

AIRGAS USA LLC

Pharma
Pharmaceuticals

AIRGAS USA LLC is a pharmaceutical company with 5 FDA-approved products.

2013
Since
5
Drugs
-
Trials
8
New Drugs (2yr)
Modality:
4 Small Molecules

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

NITROGEN, NF
Other
Approved 2013
CARBON DIOXIDE, USP
Respiratory
Approved 2013
MEDICAL AIR, USP
Respiratory
Approved 2013
OXYGEN, USP
Respiratory
Approved 2013

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

MEDICAL AIR, USP NDA
2026-02-17
CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide
MEDICAL AIR, USP NDA
2024-07-13
medical air

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

No indication data

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • NITROGEN, NF leads revenue
  • • 4 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling